Calissio Resources Group Inc (CRGP): That is utter bullshit. The MMTLP stock...

That is utter bullshit. The MMTLP stock was

janice shell · 2023-08-13T23:34:19.2300000Z

That is utter bullshit. The MMTLP stock was cancelled on the Tuesday morning. It has not existed since then, and cannot be revived. Management announced all that in advance. I can understand that players are not happy with their non-tradable Next Bridge shares. Buy management announced well in advance that it WOULD be non-tradable. Neither FINRA nor the SEC forced management of MMAT and TRCH to cut a deal that would be so disadvantageous to shareholders. Perhaps you should lay that a the door of MMAT, and the two individuals who received Wells notices.

Play Episode

3min

Proactive - Interviews for investors

Hillcrest launches ZVS technology evaluation with global Tier 1 automotive supplier

Hillcrest Energy Technologies CEO Don Currie joined Steve Darling from Proactive to announce the launch of a technology evaluation project with a global Tier 1 automotive supplier. The project’s initial phase will assess the potential benefits of Hillcrest’s Zero Voltage Switching (ZVS) technology in next-generation inverter applications for electric vehicles. If this phase is successful and both parties agree to proceed, subsequent phases will focus on the integration and validation of ZVS technology within the supplier’s inverter platform. Currie explained that Tier 1 automotive suppliers provide fully assembled components and systems to major automakers. This particular supplier, consistently ranked among the top 15 largest by revenue, is a global leader specializing in critical EV components like inverters. With a strong presence in the industry, the supplier plays a crucial role in advancing electric vehicle technology for manufacturers worldwide. The evaluation phase will involve a series of technical assessments aimed at eliminating switching losses and improving electromagnetic compatibility (EMC) performance. The supplier will analyze efficiency, performance, and potential advantages of Hillcrest’s ZVS technology within its inverter architecture. The findings from this evaluation will determine potential next steps for further collaboration and integration. This project represents a key opportunity for Hillcrest to demonstrate the value of its ZVS technology, with the shared objective of enhancing EV inverter performance and delivering significant benefits to automotive customers. #proactiveinvestors #hillcrestenergytechnologiesltd #cse #heat #ptcqb #hlrtf

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Proactive - Interviews for investors

Data security: archTIS lands key licensing deal

archTIS Ltd CEO and Managing Director Daniel Lai talked with Proactive about a newly signed $390,000 licensing agreement with a major Japanese multinational. The deal builds on archTIS’s acquisition of Direktiv and its integration of advanced cybersecurity technology into its Trusted Data Integration platform. Lai explained that the licensing agreement enables the Japanese company—an asset services provider with operations valued at $12.5 billion—to introduce new data-centric security services into the Japanese market. “This is just another example of that occurring, which is really exciting for the company,” Lai said, referring to archTIS’s broader international expansion strategy. He noted that the company had always planned to replicate its success with the Australian Department of Defence and local defence industrial base in overseas markets, particularly those facing geopolitical pressures. Lai also highlighted progress in the US and Europe, where trials were recently completed with a large US department and NATO in the UK. Looking ahead, he remained “quietly optimistic” about meeting financial targets by June 30 and delivering further material updates to the market. He acknowledged market timing and election cycles as influencing deal flow, but said government and intelligence agency engagement continues to build momentum. Visit Proactive's YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe, and turn on notifications for future content. #archTIS #Cybersecurity #DataSecurity #LicensingDeal #JapaneseMarket #QuadAlliance #TrustedDataIntegration #GlobalExpansion #DefenseTechnology #ProactiveInvestors

Followers	2574
Posts	315492
Boards Moderated	25
Alias Born	04/12/2001

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

CRGP Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free